Valuation : Novavax, Inc.

Market Cap 1.69B 1.45B 1.36B 1.25B 2.33B 159B 2.34B 16.13B 6.26B 81.66B 6.33B 6.19B 263B P/E 2026 *
-16.4x
P/E 2027 * -45.6x
Enterprise Value 1.9B 1.64B 1.54B 1.41B 2.64B 180B 2.64B 18.22B 7.07B 92.27B 7.15B 7B 297B EV / Sales 2026 *
5.11x
EV / Sales 2027 * 7.47x
Free-Float
93.05%
Yield 2026 *
-
Yield 2027 * -
1 day+0.23%
1 week+12.28%
Current month+5.91%
1 month+32.83%
3 months-1.79%
6 months+7.26%
Current year+51.27%
1 week 7.88
Extreme 7.88
9.08
1 month 6.63
Extreme 6.63
9.08
Current year 5.74
Extreme 5.74
9.88
1 year 5.41
Extreme 5.406
9.88
3 years 4.71
Extreme 4.706
13.35
5 years 4.71
Extreme 4.706
13.35
10 years 4.71
Extreme 4.706
13.35
Manager TitleAgeSince
Chief Executive Officer 59 22/01/2023
Director of Finance/CFO 60 15/08/2021
Chief Tech/Sci/R&D Officer - 31/12/2021
Director TitleAgeSince
Director/Board Member 73 05/08/2010
Director/Board Member 66 31/10/2018
Director/Board Member 60 15/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.23%+12.28% - - 1.69B
-2.54%-2.84%-1.90%+14.52% 48.93B
-0.40%+1.03%+439.20%+499.20% 45.01B
-1.42%+2.30%+45.46%+19.36% 44.07B
-1.22%-2.31%+12.40%+71.48% 40.73B
+0.53%-1.36%+16.04%+48.23% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+22.59%+116.19% 16.5B
-1.01%+0.50%+15.83%+27.98% 14.67B
-1.65%-1.03%+77.75%+37.63% 13.77B
Average -0.80%+0.53%+78.42%+104.33% 30.55B
Weighted average by Cap. -1.02%+0.11%+94.86%+122.11%

Financials

2026 *2027 *
Net sales 373M 321M 302M 276M 516M 35.21B 517M 3.57B 1.38B 18.07B 1.4B 1.37B 58.2B 266M 229M 215M 197M 368M 25.13B 369M 2.55B 988M 12.89B 1B 978M 41.54B
Net income -108M -92.54M -87.07M -79.54M -149M -10.15B -149M -1.03B -399M -5.21B -404M -395M -16.78B -37.93M -32.64M -30.71M -28.05M -52.47M -3.58B -52.62M -363M -141M -1.84B -142M -139M -5.92B
Net Debt 219M 188M 177M 162M 303M 20.68B 304M 2.1B 813M 10.61B 822M 804M 34.18B 303M 261M 245M 224M 420M 28.63B 421M 2.9B 1.13B 14.69B 1.14B 1.11B 47.32B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
04/09/26 €8.780 +0.23% 5
03/09/26 €8.760 +0.34% 4
02/09/26 €8.730 +0.23% 2,533
01/09/26 €8.710 +5.07% 0
31/08/26 €8.290 +6.01% 2,530
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
10.22USD
Average target price
14.00USD
Spread / Average Target
+37.01%

Quarterly revenue - Rate of surprise